HAMP and Hepatic fibrosis: In the present study, we showed for the first time that the adenoviral delivery of hepcidin notably diminished hepatic fibrosis with recovery of liver function in CCl4- or BDL-induced animal models of liver fibrosis, indicating that the restoration of hepcidin expression could effectively inhibit the disease progression.